Burning Rock Biotech Reports Q1 2025 Financial Results

Burning Rock Biotech Ltd. ( (BNR) ) has released its Q1 earnings. Here is a breakdown of the information Burning Rock Biotech Ltd. presented to its investors.

Burning Rock Biotech Limited, a company specializing in next generation sequencing (NGS) technology for precision oncology, focuses on therapy selection testing for late-stage cancer patients and early cancer detection. In its first quarter of 2025, Burning Rock reported a 5.9% increase in revenue compared to the same period in 2024, reaching RMB133.1 million (US$18.3 million). The company’s gross profit rose by 13.7%, driven by cost optimization measures and increased test volumes in its pharma research and development services. Operating expenses significantly decreased by 46.8% due to budget control and headcount reduction, resulting in a reduced net loss of RMB13.5 million (US$1.9 million) compared to RMB121.5 million in the previous year.

Key financial highlights include a 79.9% increase in revenue from pharma research and development services and a 19.6% decrease in revenue from the central laboratory business. The gross margin improved to 73.2%, up from 68.2% in the previous year, reflecting effective cost management. The company also presented promising study results in oncology at major conferences, showcasing advancements in personalized minimal residual disease (MRD) assays and other cancer treatments.

Looking ahead, Burning Rock Biotech remains focused on enhancing its operational efficiency and expanding its in-hospital business, while continuing to innovate in the field of precision oncology. The company aims to leverage its technological advancements to maintain growth and improve financial performance in the coming quarters.